Reference based multiple imputation;

Slides:



Advertisements
Similar presentations
Allison Dunning, M.S. Research Biostatistician
Advertisements

Asthma Trial – a double blinded, randomized, placebo-controlled study Team Moser: Jing Dong Yan Yan Wu Haipeng Yao.
Fall 2013Biostat 5110 (Biostatistics 511) Discussion Section Week 4 Sandrine Moutou Medical Biometry I.
Study Design 121 Relapsing-remitting MS patients randomized to –Stress Management Therapy MS active treatment* 16 individual sessions conducted over 24.
Systematic Review of Literature Part XIX Analyzing and Presenting Results.
Analysis & Expressing Resultd in Clinical Trials Dr. Khalili.
Exploring uncertainty in cost effectiveness analysis NICE International and HITAP copyright © 2013 Francis Ruiz NICE International (acknowledgements to:
Session 4: Analysis and reporting Managing missing data Rob Coe (CEM, Durham) Developing a statistical analysis plan Hannah Buckley (York Trials Unit)
Missing Data and Repeated Measurements
Common Problems in Writing Statistical Plan of Clinical Trial Protocol Liying XU CCTER CUHK.
Raymond J. Carroll Texas A&M University LOCF and MMRM: Thoughts on Comparisons.
Sample Size Annie Herbert Medical Statistician Research & Development Support Unit Salford Royal Hospitals NHS Foundation Trust
The Mimix Command Reference Based Multiple Imputation For Sensitivity Analysis of Longitudinal Trials with Protocol Deviation Suzie Cro EMERGE.
Addressing missing participant data in systematic reviews: Part I – Dichotomous outcomes Elie Akl, Shanil Ebrahim, Bradley Johnston, Pablo Alonso, Matthias.
Study design P.Olliaro Nov04. Study designs: observational vs. experimental studies What happened?  Case-control study What’s happening?  Cross-sectional.
1 Multiple Imputation : Handling Interactions Michael Spratt.
Practical Missing Data Analysis in SPSS (v17 onwards) Peter T. Donnan Professor of Epidemiology and Biostatistics.
Biostatistics Case Studies 2007 Peter D. Christenson Biostatistician Session 3: Incomplete Data in Longitudinal Studies.
Consumer behavior studies1 CONSUMER BEHAVIOR STUDIES STATISTICAL ISSUES Ralph B. D’Agostino, Sr. Boston University Harvard Clinical Research Institute.
Biostatistics Case Studies 2008 Peter D. Christenson Biostatistician Session 5: Choices for Longitudinal Data Analysis.
1. Title and Abstract Improving abstracts should be a goal not only for authors but also for editors because so few citation browsers ever read more than.
Name:Shanil Ebrahim, MSc, MSc, PhD Departments of Clinical Epidemiology & Biostatistics, and Anesthesia McMaster University, Hamilton, Canada Stanford.
Biostatistics Case Studies 2006 Peter D. Christenson Biostatistician Session 4: An Alternative to Last-Observation-Carried-Forward:
Why we don’t like protocol violations Yuko Y. Palesch, PhD Medical University of South Carolina.
Simulation Study for Longitudinal Data with Nonignorable Missing Data Rong Liu, PhD Candidate Dr. Ramakrishnan, Advisor Department of Biostatistics Virginia.
Rate of Visual Field Progression in Eyes With Optic Disc Hemorrhages in the Ocular Hypertension Treatment Study De Moraes CG, Demirel S, Gardiner SK, et.
How does Biostatistics at Roche typically analyze longitudinal data
Biostatistics Case Studies Peter D. Christenson Biostatistician Session 3: Missing Data in Longitudinal Studies.
CRITICAL APPARAISAL OF A PAPER ON THERAPY 421 CORSE EVIDENCE BASED MEDICINE (EBM)
LifeCIT Development and pilot evaluation of a web-supported programme of Constraint Induced Therapy following stroke (LifeCIT) Meagher C 1, Conlon A 2,
Reference based sensitivity analysis for clinical trials with missing data via multiple imputation Suzie Cro 1,2, Mike Kenward 2, James Carpenter 1,2 1.
Sample Journal Club Your Name Here.
A systematic review of selected journals
From: Short-term vs Conventional Glucocorticoid Therapy in Acute Exacerbations of Chronic Obstructive Pulmonary DiseaseThe REDUCE Randomized Clinical Trial.
Francis KL Chan Department of Medicine & Therapeutics CUHK
MISSING DATA AND DROPOUT
Primer on Adjusted Indirect Comparison Meta-Analyses
The Centre for Longitudinal Studies Missing Data Strategy
Strategies to incorporate pharmacoeconomics into pharmacotherapy
Challenges of statistical analysis in surgical trials
Brennan Kahan NIHR Doctoral Research Fellow
Sensitivity analyses for missing not at random outcomes in clinical trials (Invited Session 1.2: Recent Advances in Methods for Handling Missing Data in.
Re-randomising patients within clinical trials
Multiple Imputation Using Stata
Copyright © 2013 American Medical Association. All rights reserved.
Analyzing Intervention Studies
Filming: 15th of Febuary 2016, London, UK
Aligning Estimands and Estimators – A Case Study Sept 13, 2018 Elena Polverejan Vladimir Dragalin Quantitative Sciences Janssen R&D, Johnson & Johnson.
Alalia Berry, MD, William W. Busse, MD 
Alcohol, Other Drugs, and Health: Current Evidence May-June, 2018
Evidence Based Practice 3
Clinical Trial of Vadadustat in Patients with Anemia Secondary to Stage 3 or 4 Chronic Kidney Disease Martin et al. Am J Nephrol 2017;45: (DOI:
JAMA Ophthalmology Journal Club Slides: Outcomes of the Veterans Affairs Low Vision Intervention Trial II Stelmack JA, Tang XC, Wei Y, et al; LOVIT II.
Mark Rothmann U.S. Food and Drug Administration September 14, 2018
Common Problems in Writing Statistical Plan of Clinical Trial Protocol
The Effect of Tiotropium in Symptomatic Asthma Despite Low- to Medium-Dose Inhaled Corticosteroids: A Randomized Controlled Trial  Pierluigi Paggiaro,
An Introductory Tutorial
Q&A – studying medicine or health-related topics at university
OSLER Trial design: Patients from five phase 2 trials and seven phase 3 trials with evolocumab were invited to participate in the OSLER extension program,
Masterclass on lifestyle change How to help patients lose weight?
Modelled mean (SEM) observed forced vital capacity (FVC) volume change from baseline (mL) over time by dose intensity (>90%, ≤90%), based on actual dose.
Steps in the Research Process
Subgroup analysis. Subgroup analysis. Effect of vitamin D supplementation on outcome variables in subgroups defined by baseline levels of the respective.
Clinical and patient-reported outcomes for patients randomised to CZP 200 mg Q2W and CZP 400 mg Q4W to week 96. Clinical and patient-reported outcomes.
What Do We Know About Estimators for the Treatment Policy Estimand
Budesonide delivered by Turbuhaler is effective in a dose-dependent fashion when used in the treatment of adult patients with chronic asthma  William.
Larry C. Borish, MDa, Harold S
Björn Bornkamp, Georgina Bermann
Effects of reslizumab on lung function (forced expiratory volume in 1 s; FEV1) in Global Initiative for Asthma (GINA) Step 4 and 5 patients. Effects of.
How Should We Select and Define Trial Estimands
Presentation transcript:

Reference based multiple imputation; for sensitivity analysis of clinical trials with missing data Suzie Cro MRC Clinical Trials Unit at UCL The London School of Hygiene and Tropical Medicine

Outline Reference based multiple imputation; asthma trial The mimix command Sensitivity analysis example 1; asthma trial Sensitivity analysis example 2; peer review study

Example - asthma trial Placebo vs. Budesonide for patients with chronic asthma Forced Expiratory Volume in 1 second (FEV1) recorded at baseline, 2, 4, 8 and 12 weeks Primary outcome: mean treatment group difference at 12 weeks adjusted for baseline Only 38/90 Placebo and 72/90 Budesonide were observed at 12 weeks Busse et al. (1998)

Example - asthma trial Any analysis must make an untestable assumption about the unobserved data Wrong assumption  biased treatment estimate Primary analysis – Missing-at-Random (MAR) A set of analyses where the missing data is handled in different ways as compared to the primary analysis should be undertaken

Example - asthma trial - MAR Time (weeks) Placebo MAR means Active MAR means

Example - asthma trial - MAR Time (weeks) Placebo MAR means Active MAR means Observed FEV1

Example - asthma trial - MAR Time (weeks) Placebo MAR means Active MAR means Observed FEV1

Example - asthma trial - MAR Time (weeks) Placebo MAR means Active MAR means Observed FEV1 Imputed FEV1

Multiple imputation

Multiple imputation

Multiple imputation

Multiple imputation

Multiple imputation

Asthma trial - MAR Time (weeks) Placebo MAR means Active MAR means Observed FEV1 Imputed FEV1

Asthma trial - Jump to reference Time (weeks) Placebo MAR means Active MAR means Observed FEV1 Imputed FEV1

Asthma trial - Copy reference Time (weeks) Placebo MAR means Active MAR means Observed FEV1 Imputed FEV1

Asthma trial - Copy increments in reference Time (weeks) Placebo MAR means Active MAR means Observed FEV1 Imputed FEV1

Asthma trial - Last mean carried forward Time (weeks) Placebo MAR means Active MAR means Observed FEV1 Imputed FEV1

Reference based sensitivity analysis Comparison of results under different reference based assumptions allows us to determine the robustness of results Interim missing observations may often be imputed under on-treatment MAR, or under one of the outlined assumptions

mimix The mimix command conducts multiple imputation under the 5 reference based assumptions Optionally allows users to conduct analysis with two in-built analysis options; regress or mixed Syntax:

Asthma trial

Asthma trial

Asthma trial

Asthma trial

Asthma trial

Specifying the imputation method - 1 Name to specify in method() Missing at random (MAR) mar Jump to reference j2r Last mean carried forward lmcf Copy increments in reference cir or ciir Copy reference cr For j2r, cir or cr also require refgroup() to specify the reference group

Asthma trial - results Analysis Treat Est. Std. Err. P-value Primary – MAR 0.323 0.104 0.002 Last mean carried forward 0.296 0.096 0.003 Copy placebo 0.289 0.101 0.005 Copy active 0.251 0.082 Jump to placebo 0.226 0.103 0.029 Jump to active 0.128 0.095 0.181 Copy increments in placebo 0.281 0.007 Copy increments in active 0.277 0.001

Asthma trial - results Analysis Treat Est. Std. Err. P-value Primary – MAR 0.323 0.104 0.002 Last mean carried forward 0.296 0.096 0.003 Copy placebo 0.289 0.101 0.005 Copy active 0.251 0.082 Jump to placebo 0.226 0.103 0.029 Jump to active 0.128 0.095 0.181 Copy increments in placebo 0.281 0.007 Copy increments in active 0.277 0.001

mimix - behind the scenes…

Example 2 - Reviewer study Schroter et al. (2004) performed a single blind RCT among BMJ reviewers to compare: - no training - self-taught training Participants sent a baseline paper to review (paper 1) 2-3 months later sent second paper to review Quality of review measured by the mean (2 raters) Review Quality Instrument, range 1 to 5

Example 2 - Reviewer study Quality of baseline review: No intervention Self training n mean SD Returned paper 2 162 2.65 0.81 120 2.80 0.62 Did not return paper 2 11 3.02 0.50 46 2.55 0.75

Example 2 - Reviewer study Quality of baseline review: Primary analysis – MAR assumption What if participants who did not return paper 2 behaved like the no intervention group? No intervention Self training n mean SD Returned paper 2 162 2.65 0.81 120 2.80 0.62 Did not return paper 2 11 3.02 0.50 46 2.55 0.75

Example 2 - Reviewer study

Example 2 - Reviewer study

Example 2 - Reviewer study

Example 2 - Reviewer study Analysis Treat Est. Std. Err. P-value Primary – MAR 0.239 0.070 0.001 Copy no intervention 0.172 0.069 0.013 The intervention effect is slightly reduced under copy no intervention but it remains statistically significant

Specifying the imputation method - 2 For individual specific imputation methods use methodvar(varname) option Where varname defines the imputation method for each individual – must be constant over time refgroupvar(varname) defines individual specific reference group

Acknowledgements Adaptation of a SAS macro written by James Roger Thanks to Tim Morris for his comments and editions which helped to improve the programme James Carpenter, Mike Kenward

Carpenter JR, Roger JH, Kenward MG, Analysis of Longitudinal Trials with protocol deviation: a framework for relevant accessible assumptions and inference via multiple imputation, Journal of Biopharmaceutical Statistics, 23:1352-1371, 2013. Cro S, Morris TP, Kenward MG, Carpenter JR, Reference-based sensitivity analysis via multiple imputation for longitudinal trials with protocol deviation, Stata Journal, 16:2:443-463, 2016.